Portfolio: Select Case Studies
For confidentiality and compliance purposes, key identifying details and numbers have been altered.
Media Features
CRISPR/Cas9: Outlook from an investor's perspective (Labiotech - 2022)
Six biotech stocks trading below cash right now (Labiotech - 2022)
Gene therapy approval “game changer” in hemophilia B treatment (Labiotech – 2022)
The biggest biotech trends that will shape 2023 (Labiotech – 2023)
5 Clinical-Stage Cell and Gene Therapy Startups Leading the Pack (Inside Precision Medicine - 2023)
5 advancements in kidney disease research over the past year (Labiotech - 2023)
5 advancements in Down syndrome research over the past year (Labiotech - 2023)
European Regenerative Medicine Snapshot: Dealmaking on Uptick (Mergermarket - 2023)
European biotech companies with oncology projects attract Big Pharma (Mergermarket - 2024)
5 Key Startups Bringing Digital Pathology Into Focus (Inside Precision Medicine - 2024)
Megadeals continued amid sluggish investments and M&A in 2024 (BioXconomy - 2024)
Contact Me - For Consulting Or Media Requests
Note: I do not provide valuation or financial modeling services. This is not financial or investment advice. I reserve the right to reject engagements in case of conflict of interest or other compliance considerations.